WALTHAM, MA, USA I July 9, 2025 I Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for ...

BASEL, Switzerland / MUNICH, Germany I July 10, 2025 I NUCLIDIUM, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

CHICAGO, IL, USA I July 09, 2025 I MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted ...

Tegoprubart to be Used as Immunosuppressive Agent in Cohort C of Sernova’s Phase 1/2 Cell Pouch Bio-hybrid Organ Clinical Trial in Patients with Type 1 Diabetes ...

OSLO, Norway and CAMBRIDGE, MA, USA I July 9, 2025 I Actithera, a radiopharmaceutical biotech company translating medicinal chemistry insights into ...

SHANGHAI, China I July 9, 2025 I Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma"), a clinical-stage biopharmaceutical company dedicated to innovative ...

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of ...

PRAGUE, Czech Republic I July 9, 2025 I Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for ...

MARTINSRIED, Germany, and MARSEILLE, France I July 10, 2025 I Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of ...

GUANGZHOU, China I July 2, 2025 I Bio-Thera Solutions, Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced ...

CAMBRIDGE, MA, USA I June 21, 2025 I MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of ...

The study met its primary and all secondary efficacy endpoints for all dose groups Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic ...